KIDS Valuation

OrthoPediatrics Corp

Add to Watchlist

Advanced Chart

20.110

+0.86(4.468%)1D

Overview
Forecast
Valuation
Earnings

KIDS Relative Valuation

KIDS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KIDS is overvalued; if below, it's undervalued.

Historical Valuation

OrthoPediatrics Corp (KIDS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.89 is considered Undervalued compared with the five-year average of -45.64. The fair price of OrthoPediatrics Corp (KIDS) is between 31.39 to 83.63 according to relative valuation methord. Compared to the current price of 19.25 USD , OrthoPediatrics Corp is Undervalued By 38.68%.

Relative Value

Fair Zone

31.39-83.63

Current Price：19.25

38.68%

Undervalued

-15.23

Trailing

Forward

25.42

EV/EBITDA

OrthoPediatrics Corp. (KIDS) has a current EV/EBITDA of 25.42. The 5-year average EV/EBITDA is 287.84. The thresholds are as follows: Strongly Undervalued below -591.30, Undervalued between -591.30 and -151.73, Fairly Valued between 727.42 and -151.73, Overvalued between 727.42 and 1166.99, and Strongly Overvalued above 1166.99. The current Forward EV/EBITDA of 25.42 falls within the Historic Trend Line -Fairly Valued range.

-19.10

EV/EBIT

OrthoPediatrics Corp. (KIDS) has a current EV/EBIT of -19.10. The 5-year average EV/EBIT is -53.66. The thresholds are as follows: Strongly Undervalued below -113.62, Undervalued between -113.62 and -83.64, Fairly Valued between -23.67 and -83.64, Overvalued between -23.67 and 6.31, and Strongly Overvalued above 6.31. The current Forward EV/EBIT of -19.10 falls within the Overvalued range.

1.86

OrthoPediatrics Corp. (KIDS) has a current PS of 1.86. The 5-year average PS is 6.33. The thresholds are as follows: Strongly Undervalued below -0.10, Undervalued between -0.10 and 3.11, Fairly Valued between 9.54 and 3.11, Overvalued between 9.54 and 12.75, and Strongly Overvalued above 12.75. The current Forward PS of 1.86 falls within the Undervalued range.

0.00

P/OCF

OrthoPediatrics Corp. (KIDS) has a current P/OCF of 0.00. The 5-year average P/OCF is -16.34. The thresholds are as follows: Strongly Undervalued below -188.12, Undervalued between -188.12 and -102.23, Fairly Valued between 69.55 and -102.23, Overvalued between 69.55 and 155.44, and Strongly Overvalued above 155.44. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

OrthoPediatrics Corp. (KIDS) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.18. The thresholds are as follows: Strongly Undervalued below -31.38, Undervalued between -31.38 and -17.28, Fairly Valued between 10.91 and -17.28, Overvalued between 10.91 and 25.01, and Strongly Overvalued above 25.01. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

OrthoPediatrics Corp (KIDS) has a current Price-to-Book (P/B) ratio of 1.36. Compared to its 3-year average P/B ratio of 2.05 , the current P/B ratio is approximately -33.70% higher. Relative to its 5-year average P/B ratio of 3.09, the current P/B ratio is about -56.12% higher. OrthoPediatrics Corp (KIDS) has a Forward Free Cash Flow (FCF) yield of approximately -7.67%. Compared to its 3-year average FCF yield of -5.63%, the current FCF yield is approximately 36.30% lower. Relative to its 5-year average FCF yield of -4.38% , the current FCF yield is about 75.06% lower.

1.36

P/B

Median3y

2.05

Median5y

3.09

-7.81

FCF Yield

Median3y

-5.63

Median5y

-4.38

Competitors Valuation Multiple

The average P/S ratio for KIDS's competitors is 2.55, providing a benchmark for relative valuation. OrthoPediatrics Corp Corp (KIDS) exhibits a P/S ratio of 1.86, which is -27.01% above the industry average. Given its robust revenue growth of 15.68%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Standard BioTools Inc

Cytek Biosciences Inc

Performance Decomposition

Market capitalization of KIDS decreased by 28.99% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 52.80M to 61.08M.

The secondary factor is the Margin Expansion, contributed 2.01%to the performance.

Overall, the performance of KIDS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

15.68%

52.80M → 61.08M

Revenue Growth

2.01%

-11.42 → -11.65

Margin Expansion

-46.68%

-20.10 → -10.72

P/E Change

-28.99%